# Trending Content OS — Daily Run
**Run date:** 2026-10-29

---

## 1. Preflight Summary

| Check | Status |
|---|---|
| All 7 configs + CLAUDE.md sections loaded | ✅ |
| `site_niche` set | ✅ "health and wellness" |
| `target_audience` set | ✅ |
| `site_url` set | ⚠️ Blank — self-check skipped, competitor-list fallback used (configs/competitor_list.yaml) |
| `minimum_trend_strength_score` / `minimum_opportunity_score` | ✅ 50 / 55 |
| SerpAPI connected | ✅ |
| Google Trends available | ✅ via injected pre-fetch (`search_velocity_source: google_trends`) |
| Google News Radar injected | ✅ 144 unique headlines across 12 queries |
| `data/deferred_topics.yaml` due items | None past `recheck_on` |
| Recurring-theme check (run history) | Ebola/DRC, FDA recalls, and GLP-1/weight-loss coverage have each appeared in 3+ consecutive runs → flagged recurring, deprioritized unless genuinely new development |

**Decision:** `next_action: run_signal_listener` — all required sections present, proceeding with full pipeline.

---

## 2. Google News Radar Coverage Summary

Clusters identified across the 144-headline radar, and disposition:

| Cluster | Disposition | Why |
|---|---|---|
| **HHS/RFK unapproved "wellness peptides" policy** ([Reuters](https://www.reuters.com/legal/litigation/us-health-department-allow-temporary-sale-some-unapproved-peptides-2026-10-28/), [ABC News](https://abcnews.com/Health/wellness-peptides-become-widely-hhs/story?id=137650076)) | **Retained (P1)** | New regulatory action, directly matches a literal top rising Google Trends query ("why did the US ease access to unapproved wellness peptides and what are the safety concerns?") — rare full convergence of News + Trends |
| **FDA recall wave** (Gatorade dyes, Walmart Great Value fruit cocktail, Medtronic leads, Haifa sprats, toothpaste, butter) | **Split** | Gatorade + fruit cocktail recalls retained (new); toothpaste/butter recalls rejected as `existing` (already covered 10/22–10/28); Medtronic + sprats routed to Monitor (thin sourcing, low trend velocity) |
| **Climate-health emergency (Lancet Countdown/WHO)** ([WHO](https://www.who.int/news/item/28-10-2026-climate-change-is-a-growing-health-emergency--lancet-countdown-warns), [ABC News](https://abcnews.com/US/climate-change-global-health-emergency-harms-accelerating-lancet/story?id=137598966)) | **Rejected — existing** | Already covered 10/28; today's coverage is same-day pickup, no new development |
| **Medical study digest** (long COVID, colorectal cancer immune-evasion, genetics of personality, alcohol mortality, medical debt) | **Split** | Stanford long COVID study retained (new, institutional primary); USF colorectal, Penn genetics, Ohio medical debt rejected as `existing`; News-Medical alcohol-mortality study rejected at Skill 02b (no traceable journal/DOI) |
| **FDA-approved rectal cancer immunotherapy** ([MSK](https://www.mskcc.org/news/rectal-cancer-disappears-after-experimental-use-immunotherapy)) | **Retained (P2)** | New FDA approval, strong institutional primary source, high patient relevance |
| **Clinical trial access/business expansion** (Walmart/Care Access centers, Ochsner/Paradigm, Cleveland Clinic AI award, congressional rural-trial bill) | **Rejected — off-category** | Pure business/PR/legislative-process framing, weak audience relevance for a general health reader |
| **Wellness lifestyle/PR cluster** (Gen Z "wellness darties," wellness tokens, gym expansions, wellness fairs, PwC wellness market report, wellness counseling profile) | **Rejected — off-category/low value** | Local institutional PR or generic trend fluff, no evidence-based health angle |
| **Health politics/personnel** (Calley Means resignation, Epic/STAT antitrust) | **Rejected — off-category** | Political personnel and pure health-tech business news |
| **Oura/UCSD GLP-1 wearable study** ([Fierce Healthcare](https://www.fiercehealthcare.com/health-tech/oura-uc-san-diego-health-study-glp-1-outcomes-using-continuous-smart-ring-data)) | **Rejected — weak signal** | Announcement of a research partnership, no findings yet |
| **Ongoing Ebola/DRC, GLP-1 shortage, superbug threat stories** | **Rejected — recurring/existing** | Flagged as appearing in 3+ consecutive runs with no qualifying new development today |

---

## 3. Signal Summary

```yaml
signal_summary:
  run_started_at: "2026-10-29T12:00:00Z"
  run_completed_at: "2026-10-29T12:40:00Z"
  total_signals_reviewed: 172
  total_signals_retained: 5
  total_monitored: 2
  total_rejected: 165
  google_trends_available: true
  search_velocity_source: "google_trends"
  rejection_breakdown:
    off_category: 58
    brand_safety: 2
    duplicate: 17
    weak_signal: 72
    unverified_claim: 1
    other: 15
  highest_priority_topic: "HHS eases access to unapproved wellness peptides"
  strongest_signal_source: "Reuters + Google Trends convergence (exact rising-query match)"
  tools_unavailable: []
  notes: >
    Google News Radar + Google Trends pre-fetch both available; no collector outages.
    Recurring-theme flags: Ebola/DRC outbreak, FDA recalls, and GLP-1/weight-loss stories
    have each appeared in 3+ consecutive runs — only genuinely new developments within
    those clusters (Gatorade, fruit cocktail) were retained today. site_url not configured;
    self-check skipped in favor of competitor-list fallback per configs/competitor_list.yaml.
```

---

## 4. Skill 02b — Health Claim Verification Gate: Routing Summary

| Candidate | Risk type | Gate result | Primary source | Notes |
|---|---|---|---|---|
| Wellness peptides policy | dosage/safety guidance | **Pass** | Trusted secondary (Reuters, naming HHS Secretary + action directly) | ⚠️ Confirm FDA/HHS official notice before publishing dosage/safety specifics |
| Gatorade recall | recall | **Pass** | Trusted secondary naming FDA | Single-source evidence — confirm FDA enforcement report |
| Walmart fruit cocktail recall | recall | **Pass** | Trusted secondary naming FDA + Trends corroboration | Regional-only source — confirm national scope |
| MSK rectal cancer immunotherapy | drug/treatment claim | **Pass** | Institutional (MSK, tier-1) | Clarify biomarker-defined patient subset, not all rectal cancer |
| Long COVID (Stanford) | medical study | **Pass** | Institutional (Stanford, tier-1) | Headline is vague — confirm specific finding before drafting |
| Medtronic defibrillation leads recall | recall (device) | **Pass** (gate) / **Monitor** (Skill 04 — trend score 36.5, below 50 threshold) | Trusted secondary (trade pub) | Single, lower-tier source |
| Haifa Smoked Fish sprats recall | recall | **Pass** (gate) / **Monitor** (Skill 04 — trend score 43.5, below threshold) | FDA.gov direct notice | Niche product, low audience relevance |
| Beer/wine/spirits mortality study | medical study | **Reject** | None traceable | News-Medical secondary does not name journal/DOI/researcher — unverifiable per gate rules |

---

## 5. Final Priority Board

| Priority | Topic | Primary Entity | Signal Type | Category | Trend | Opp. | Discover | Urgency | Confidence | Status | Sources | Count |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **P1** | HHS eases access to unapproved wellness peptides | HHS / RFK Kennedy | policy_or_regulatory_change | FDA and CDC regulatory updates | 70.5 | 85 | 4 | today | medium | new | [Reuters](https://www.reuters.com/legal/litigation/us-health-department-allow-temporary-sale-some-unapproved-peptides-2026-10-28/), [ABC News](https://abcnews.com/Health/wellness-peptides-become-widely-hhs/story?id=137650076) | 2 |
| **P2** | Gatorade recall — 122K+ cases, undeclared food dyes | Gatorade / PepsiCo | recall | FDA and CDC regulatory updates | 65.3 | 71.8 | 4 | today | medium | new | [ABC News](https://abcnews.com/GMA/Food/122k-cases-gatorade-recalled-due-undeclared-food-dyes/story?id=137002347) | 1 |
| **P2** | FDA approves immunotherapy-only treatment for rectal cancer (no surgery) | Memorial Sloan Kettering | drug_or_treatment_claim | medical research and clinical trials | 55.5 | 75.3 | 4 | this_week | medium | new | [MSK](https://www.mskcc.org/news/rectal-cancer-disappears-after-experimental-use-immunotherapy) | 1 |
| **P3** | Walmart Great Value fruit cocktail recall | Walmart | recall | FDA and CDC regulatory updates | 50.5 | 66.3 | 3 | today | medium | new | [Detroit Free Press](https://www.freep.com/story/entertainment/dining/2026/10/27/recall-great-value-walmart-fruit-cocktail-michigan-fda/92456963007/) | 1 |
| **P3** | Stanford study refines understanding of long COVID | Stanford University | study_or_research | infectious disease | 50.5 | 67.3 | 3 | this_week | medium | new | [Stanford](https://news.stanford.edu/stories/2026/10/long-covid-health-affects-study-design) | 1 |
| **P5 (Monitor)** | Medtronic defibrillation leads recall | Medtronic | recall | chronic disease management | 36.5 | — | — | — | low | new | [Cardiovascular Business](https://cardiovascularbusiness.com/topics/clinical/heart-rhythm/medtronic-recalls-defibrillation-leads-due-risk-implant-issues) | 1 |
| **P5 (Monitor)** | Cold smoked sprats recall | Haifa Smoked Fish | recall | FDA and CDC regulatory updates | 43.5 | — | — | — | low | new | [FDA.gov](https://www.fda.gov/food/alerts-advisories-safety-information/fda-advises-not-eat-sell-or-serve-cold-smoked-sprats-sold-haifa-smoked-fish-inc) | 1 |

```yaml
summary:
  total_topics: 7
  high_priority_count: 1
  immediate_actions: "Publish peptides explainer within 24–48h while search interest is active; confirm FDA/HHS primary notice before finalizing dosage/safety language."
```

---

## 6. Editorial Briefs

### P1 — HHS eases access to unapproved wellness peptides
```yaml
brief:
  primary_headline: "HHS Just Made Unapproved 'Wellness Peptides' Legal to Sell — Here's What That Means for Your Safety"
  alternate_headlines:
    - "The US Just Eased Rules on Unregulated Peptides. Doctors Have Questions."
    - "Wellness Peptides Are About to Flood the Market — What the FDA Isn't Checking"
    - "RFK Jr.'s HHS Opens the Door to Unapproved Peptides: What to Know Before You Buy"
  topic: "HHS policy change easing access to unapproved wellness peptides"
  primary_entity: "HHS / Secretary Robert F. Kennedy Jr."
  search_intent: "informational / skeptical"
  angle: "Consumer-safety explainer — what's now accessible, what 'unapproved' means in FDA terms, and what doctors say about self-administering unregulated peptides"
  why_now: "Policy announced 10/28 by HHS Secretary Kennedy; directly matches a top rising Google search query asking exactly what the safety concerns are — zero authoritative consumer answer exists yet"
  integrity_flags:
    - "⚠️ No direct FDA/HHS notice link retrieved yet — confirm via FDA.gov/HHS.gov before publishing dosage/compliance specifics"
    - "⚠️ Avoid framing 'unapproved' as synonymous with 'dangerous' or 'harmless' — distinguish unverified manufacturing/dosing from inherent danger"
  outline:
    intro: "What just changed and why it's trending"
    sections: ["What 'unapproved peptide' means in FDA terms", "Which peptides are affected (BPC-157-style compounded products)", "Why HHS made this move", "What doctors/pharmacists say about risk", "What to do if you're considering one"]
    conclusion: "Watch for the formal FDA/HHS notice and compliance timeline"
  key_data_points:
    - "Policy announced 10/28/2026 by HHS Secretary Kennedy (Reuters)"
    - "Corroborated same-day by ABC News"
    - "Embedded as a top rising Google Trends 'wellness' query"
  source_plan:
    - {publisher: "Reuters", url: "https://www.reuters.com/legal/litigation/us-health-department-allow-temporary-sale-some-unapproved-peptides-2026-10-28/", tier: 1, used_for: "Primary reporting of policy action"}
    - {publisher: "ABC News", url: "https://abcnews.com/Health/wellness-peptides-become-widely-hhs/story?id=137650076", tier: 1, used_for: "Corroboration"}
    - {publisher: "FDA.gov", url: "[URL unverified]", tier: 1, used_for: "Official notice — locate before publish"}
  evidence_requirements: "Moderate — needs FDA compounding framework context (503A/503B) + one clinical pharmacologist quote"
  expert_sources:
    - {type: "clinical pharmacologist or endocrinologist", name: "TBD — source via published commentary", reason: "Peptide safety and compounding risk context"}
  internal_links: []
  visual_brief: "Approved vs. unapproved pathway diagram; avoid alarmist syringe/vial stock photos"
  seo:
    primary_keyword: "unapproved wellness peptides safety"
    supporting_keywords: ["HHS peptides policy", "BPC-157 legal status", "compounded peptides FDA rules"]
    format: "explainer/FAQ"
    schema_markup: "FAQPage"
    cluster: "FDA regulatory updates"
  discover_notes: "Discover score 4 — exact query-match entity clarity, but durability depends on whether this remains an active regulatory story"
  key_takeaways: ["Policy opens access to previously unapproved peptides", "'Unapproved' ≠ automatically unsafe, but means unverified manufacturing/dosing", "Confirm primary source before publishing specific guidance"]
  estimated_word_count: "1,100–1,300"
execution_notes: "Time-sensitive — publish within 24–48h; update once FDA/HHS notice located"
confidence: medium
```

### P2 — Gatorade recall
```yaml
brief:
  primary_headline: "Gatorade Recalls Over 122,000 Cases Nationwide Over Undeclared Food Dyes — What to Know"
  alternate_headlines: ["Is Your Gatorade Recalled? FDA Flags Undeclared Dyes in 122K+ Cases", "Gatorade Recall 2026: Affected Lots and What PepsiCo Says"]
  topic: "Gatorade recall — undeclared food dyes"
  primary_entity: "Gatorade / PepsiCo"
  search_intent: "informational"
  angle: "Direct consumer-safety utility — affected lots, why undeclared dyes matter, what to do"
  why_now: "FDA-confirmed recall of a major, widely consumed brand (122,000+ cases) reported 10/27 — mass consumer reach, labeling/allergen safety issue"
  integrity_flags: ["⚠️ Single news source in evidence set — confirm full lot/UPC list against FDA enforcement report before publishing"]
  outline:
    intro: "Scope of the recall"
    sections: ["What was recalled and why", "Why undeclared dyes matter (allergy/sensitivity risk)", "What to do if you have it"]
    conclusion: "How to check for updates"
  key_data_points: ["122,000+ cases recalled (ABC News, 10/27)", "Reason: undeclared food dyes", "FDA-confirmed"]
  source_plan:
    - {publisher: "ABC News", url: "https://abcnews.com/GMA/Food/122k-cases-gatorade-recalled-due-undeclared-food-dyes/story?id=137002347", tier: 1, used_for: "Primary reporting naming FDA"}
    - {publisher: "FDA.gov", url: "[URL unverified]", tier: 1, used_for: "Enforcement report — locate before publish"}
  evidence_requirements: "Light — standard recall reporting"
  expert_sources: [{type: "RDN (optional)", name: "TBD", reason: "Comment on food dye sensitivities"}]
  internal_links: []
  visual_brief: "Product photo with affected flavor/lot codes overlaid"
  seo: {primary_keyword: "Gatorade recall 2026", supporting_keywords: ["Gatorade food dye recall", "is my Gatorade recalled"], format: "news explainer", schema_markup: "NewsArticle", cluster: "FDA recalls"}
  discover_notes: "Discover score 4 — recognizable brand, natural query fit, FDA source locatable; ephemeral news-cycle topic"
  key_takeaways: ["Scope and affected products", "Why undeclared dyes matter", "Action steps for consumers"]
  estimated_word_count: "700–900"
confidence: medium
```

### P2 — FDA-approved immunotherapy-only rectal cancer treatment
```yaml
brief:
  primary_headline: "FDA Approves Immunotherapy-Only Treatment for Some Rectal Cancers — No Surgery Required"
  alternate_headlines: ["This Rectal Cancer Treatment Skips Surgery Entirely. Here's Who Qualifies", "What the New FDA-Approved Immunotherapy Approach Means for Patients"]
  topic: "FDA approval of immunotherapy-only rectal cancer treatment"
  primary_entity: "Memorial Sloan Kettering / FDA"
  search_intent: "informational / evaluative"
  angle: "Patient-facing explainer on who qualifies (biomarker-defined subset), what the approval really changes, and realistic expectations"
  why_now: "FDA approval of a non-surgical immunotherapy pathway for a defined rectal cancer subset — landmark shift from default surgery, explained by the originating institution 10/25"
  integrity_flags:
    - "⚠️ Single-source institutional coverage — clearly state this applies to a biomarker-defined subset, not rectal cancer broadly"
    - "⚠️ Distinguish FDA-approved indication from earlier small-trial findings on the same approach"
  outline:
    intro: "What the approval covers"
    sections: ["What 'immunotherapy-only' means", "Who actually qualifies (MSI-high/dMMR)", "How this differs from standard surgery", "What oncologists say"]
    conclusion: "What patients should ask their care team"
  key_data_points: ["FDA approval announced via MSK news release, 10/25/2026", "Applies to a defined rectal cancer patient subset"]
  source_plan:
    - {publisher: "Memorial Sloan Kettering", url: "https://www.mskcc.org/news/rectal-cancer-disappears-after-experimental-use-immunotherapy", tier: 1, used_for: "Primary institutional source"}
    - {publisher: "FDA.gov", url: "[URL unverified]", tier: 1, used_for: "Approval notice — locate before publish"}
  evidence_requirements: "Moderate — needs biomarker/eligibility criteria + oncologist quote"
  expert_sources: [{type: "colorectal oncologist", name: "MSK-affiliated researcher (named in source)", reason: "Eligibility and outcomes context"}]
  internal_links: []
  visual_brief: "Simple treatment-pathway graphic (surgery vs. immunotherapy-only); avoid 'cancer vanishes' framing"
  seo: {primary_keyword: "immunotherapy rectal cancer FDA approval", supporting_keywords: ["rectal cancer no surgery treatment", "dMMR rectal cancer immunotherapy"], format: "explainer", schema_markup: "MedicalWebPage", cluster: "medical research/oncology"}
  discover_notes: "Discover score 4 — specific entity, strong Q&A fit, durable clinical relevance"
  key_takeaways: ["Which patients qualify", "What changes in practice", "Caution against overgeneralizing"]
  estimated_word_count: "900–1,100"
confidence: medium
```

### P3 (concise) — Walmart Great Value fruit cocktail recall
```yaml
brief:
  headline: "Walmart Recalls Great Value Fruit Cocktail — Check If You're Affected"
  topic: "Walmart Great Value fruit cocktail recall"
  angle: "Quick consumer-safety utility — affected product, reason, what to do"
  key_data_points: ["Recall reported 10/27 (Detroit Free Press)", "Also a live rising Google Trends query — active consumer search demand"]
  integrity_flags: ["⚠️ Coverage is regional (Michigan-focused) — confirm full national FDA recall scope before publishing"]
  expert_type_needed: "None — standard recall reporting"
  seo: {primary_keyword: "Great Value fruit cocktail recall", format: "short news brief", serp_difficulty: "Easy"}
  sources:
    - {publisher: "Detroit Free Press", url: "https://www.freep.com/story/entertainment/dining/2026/10/27/recall-great-value-walmart-fruit-cocktail-michigan-fda/92456963007/"}
    - {publisher: "FDA.gov", url: "[URL unverified]"}
  estimated_word_count: "350–450"
```

### P3 (concise) — Long COVID study refinement (Stanford)
```yaml
brief:
  headline: "New Stanford Research Refines What We Know About Long COVID"
  topic: "Stanford study on long COVID health effects and study design"
  angle: "Explain in plain terms what changed in the research and what it means for diagnosis going forward"
  key_data_points: ["Stanford University news release, 10/27/2026"]
  integrity_flags: ["⚠️ Headline framing is vague ('refines understanding') — confirm specific effect-size/methodological finding before drafting"]
  expert_type_needed: "Infectious disease epidemiologist or long COVID researcher (ideally study author)"
  seo: {primary_keyword: "long COVID new research 2026", format: "research explainer", serp_difficulty: "Medium"}
  sources:
    - {publisher: "Stanford University", url: "https://news.stanford.edu/stories/2026/10/long-covid-health-affects-study-design"}
  estimated_word_count: "500–650"
```

---

## 7. Rejected Topics Log

| Topic | Reason |
|---|---|
| Lancet Countdown climate-health report | Existing — covered 10/28, no new development |
| Miyoko's/Prosperity Organic butter recall | Existing — covered 10/28 |
| Brush Buddies toothpaste recall | Existing — covered 10/23 |
| USF/Tampa General colorectal cancer immune-evasion study | Existing — covered 10/27 |
| Penn Medicine genetics of personality | Existing — covered 10/26 |
| NIH precision T-cell therapy | Existing — covered 10/24 |
| PTSD treatment 68% remission | Existing — covered 10/26 |
| WHO Ebola vaccine trial DRC | Existing — covered 10/25 |
| Ohio/KFF medical debt study | Existing — overlaps 10/27 KFF/Commonwealth Fund story; incremental stat only |
| Calley Means HHS resignation | Off-category — political personnel |
| STAT Epic EHR antitrust | Off-category — pure health-tech business |
| Anthropic/Claude drug development | Off-category — pure tech/business |
| Walmart/Care Access clinical trial centers | Off-category — corporate expansion, weak audience relevance |
| Cleveland ClinicAI clinical trial matching award | Off-category — PR/award announcement, low news value |
| Ochsner/Paradigm clinical trial expansion (Gulf South) | Off-category — local/regional, too narrow |
| Congressional rural clinical trial access bill (Morgan Griffith) | Off-category — legislative process, political |
| VCU NIH heart failure grant | Off-category — narrow institutional funding announcement |
| Purdue "researchers seeking participants" | Weak signal — generic, no audience value |
| Nature "no direct benefit" clinical research ethics piece | Weak signal — too academic/niche, low opportunity |
| AI-in-doctor's-visit billing findings | Weak signal — single thin trade-pub source |
| Oura/UC San Diego GLP-1 smart ring study | Weak signal — partnership announced, no findings yet |
| Beer/wine/spirits mortality study (News-Medical) | **Unverifiable claim (Skill 02b reject)** — secondary source does not name journal/DOI/researcher |
| Gen Z "wellness darties" / wellness tokens / gym expansions / wellness fairs / PwC wellness market report / wellness counseling profile / Granada Theater wellness brand purchase / VCU Wellness Week | Off-category — local PR, lifestyle fluff, no evidence-based health angle |
| Wedgewood pet medicine recall | Excluded category — pet health |
| "Morgan — Nobody Wants This" weight loss chatter | Brand safety — celebrity/entertainment gossip |
| Trends autocomplete noise (ernie johnson health, health insurance agency, fairmount behavioral health system, advocate health careers, mcrib nutrition facts, magnesium bisglycinate gummies review, beller nutrition, ai personal assistant, ai image enhancer, aura points/slang, viral tiktok trends) | Weak signal — no news/search corroboration, not actionable editorial topics |
| GLP-1/retatrutide ad-ruling chatter (Eli Lilly) | Weak signal — no corroborating article in radar; insufficient evidence this run, watch for development |
| Ebola/DRC outbreak, CDC superbug list, GLP-1 shortage | Recurring — flagged in 3+ consecutive runs, no new development today |

---

## 8. Integrity Flags (Consolidated)

⚠️ **HHS wellness peptides policy** — No direct FDA/HHS notice link retrieved; confirm official source before publishing dosage/compliance specifics. Avoid framing "unapproved" as synonymous with either "dangerous" or "harmless."

⚠️ **Gatorade recall** — Single news source (ABC News) in evidence set; confirm full lot/UPC code list against the FDA enforcement report before publishing.

⚠️ **Walmart Great Value fruit cocktail recall** — Coverage is regional (Michigan-only, Detroit Free Press); confirm full national FDA recall scope and affected states before publishing.

⚠️ **MSK rectal cancer immunotherapy approval** — Single-source institutional coverage; must clarify this applies to a specific biomarker-defined patient subset (not rectal cancer broadly) and distinguish FDA-approved indication from earlier small-trial findings.

⚠️ **Stanford long COVID study** — Headline is vague ("refines understanding"); confirm the specific effect-size or methodological finding before drafting to avoid a thin, generic writeup.

⚠️ **Medtronic defibrillation leads recall (Monitor)** — Single, lower-tier trade source; verify against FDA MedWatch device recall database before any future brief.

⚠️ **Haifa Smoked Fish sprats recall (Monitor)** — Valid FDA.gov primary source but low audience relevance/niche product; trend score below publication threshold.

---

## 9. Run Notes

- Google Trends and Google News Radar were both available this run via the injected SerpAPI pre-fetch; no collector outages to report.
- `site_url` is not configured — duplicate/SERP-gap checks used the competitor-list fallback (configs/competitor_list.yaml) rather than a live self-check. This limits certainty on `content_status: new` calls; all such candidates carry that caveat.
- Recent-coverage dedup was applied against the last 7 days of logged topics: 9 candidates were cut as `existing` with no qualifying new development, and one (Ohio/KFF medical debt) was borderline — it added a new stat but not a materially new storyline, so it was rejected rather than marked `update`.
- Three recurring themes (Ebola/DRC outbreak, FDA recall cadence, GLP-1/weight-loss coverage) have now appeared in 3+ consecutive runs; per CLAUDE.md these are flagged for staleness review rather than defaulted back into the board. Only genuinely new developments within those clusters (Gatorade, Walmart fruit cocktail) were retained today.
- The single Skill 02b rejection (beer/wine/spirits mortality study) is a good example of the gate working as intended: a plausible, audience-relevant topic was cut purely on sourcing grounds (News-Medical did not name the underlying journal, cohort, or DOI) rather than on topical judgment.
- Two candidates passed the Skill 02b gate but were still capped at Monitor by Skill 04 on trend-strength grounds (Medtronic leads recall, Haifa sprats recall) — a reminder that gate passage and score passage are independent checks, per the pipeline design.
- No P4 (evergreen backlog) candidates were generated this run — all retained topics were news-driven with defined urgency windows. Candidate volume stayed well under `max_candidates_returned` (25), so nothing overflowed to `data/deferred_topics.yaml`.
- Dashboard output and `data/run_history.yaml` update: not executed in this conversational run (no file-system/tool access in this environment) — this report constitutes the full content of what would be written to `outputs/daily_newsroom_dashboard/2026-10-29.html` and appended to run history.